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Menopausal hormone use and ovarian cancer risk: individual 
participant meta-analysis of 52 epidemiological studies
Collaborative Group on Epidemiological Studies of Ovarian Cancer*
Summary
Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian 
cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or 
recall. We aimed to assess with minimal bias the eﬀ ects of hormone therapy on ovarian cancer risk.
Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal 
analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). 
Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) 
versus never-use.
Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone 
therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years 
of use (RR 1·43, 95% CI 1·31–1·56; p<0·0001). Combining current-or-recent use (any duration, but stopped 
<5 years before diagnosis) resulted in an RR of 1·37 (95% CI 1·29–1·46; p<0·0001); this risk was similar in European 
and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but diﬀ ered across 
the four main tumour types (heterogeneity p<0·0001), being deﬁ nitely increased only for the two most common 
types, serous (RR 1·53, 95% CI 1·40–1·66; p<0·0001) and endometrioid (1·42, 1·20–1·67; p<0·0001). Risk declined 
the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was 
still an excess of serous or endometrioid tumours (RR 1·25, 95% CI 1·07–1·46, p=0·005).
Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 
5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, 
about one extra ovarian cancer death per 1700 users.
Funding Medical Research Council, Cancer Research UK.
Copyright © Collaborative Group on Epidemiological Studies of Ovarian Cancer. Open Access article distributed 
under the terms of CC BY.
Introduction
Use of hormone therapy for the menopause increased 
rapidly during the 1990s, then halved abruptly in the 
early 2000s after publication of the Women’s Health 
Initiative, a large randomised trial,1 but has stabilised 
during the 2010s with about 6 million users in the USA 
and UK alone (ﬁ gure 1, appendix p 4).
Current hormone therapy guidelines vary in what is 
said about ovarian cancer. The European drug regulatory 
guidelines2 do not mention the disease, nor does the 
US Food and Drug Administration statement3 (based 
just on the Women’s Health Initiative, which recorded 
few ovarian cancers). UK drug regulatory guidelines4 
state that ovarian cancer might be increased by long-
term use, but were dominated by ﬁ ndings from 
one large study;5 new UK guidelines are being developed. 
The most recent WHO review was completed before 
results from most large studies were published, so 
merely concluded that there was insuﬃ  cient evidence 
about any ovarian cancer risk.6 Recently, some non-
governmental reviews have argued that a few years of 
hormone therapy use starting before the age of 60 years 
should cause no material harm.7 Most individual studies 
have, however, been too small to assess reliably any risks 
associated with use for only a few years (which is 
nowadays the usual pattern), so a systematic review of 
the worldwide epidemiological evidence is needed.
Reliable epidemiological assessment of any 
association of hormone therapy use with ovarian cancer 
requires large numbers and careful control of all 
potential sources of appreciable bias, and reviews just of 
the published evidence cannot provide this. For, 
although many studies of ovarian cancer collected some 
information about hormone therapy use, some were 
focused chieﬂ y on other issues. Hence, published data 
about hormone therapy use are available for only about 
half the studies of ovarian cancer that have relevant data 
(appendix pp 5–9). Moreover, in some of the studies 
with retrospective designs, hormone therapy users 
might have been more willing than non-users to 
participate as controls, or there might have been 
diﬀ erential recall of hormone therapy use between 
women already diagnosed with ovarian cancer and 
unaﬀ ected women. The Collaborative Group on 
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Epidemiological Studies of Ovarian Cancer was 
established in 1998 to bring together and analyse 
centrally individual participant data from all epidemio-
logical studies of ovarian cancer, assessing the risks 
associated with hormonal and other factors. To evaluate 
with minimal bias the association of ovarian cancer 
with just a few years of hormone therapy use, or with 
past use, the principal analyses review detailed data 
from those prospective studies with information about 
both duration and recency of hormone therapy use. 
Sensitivity analyses review the evidence from all studies, 
prospective or retrospective.
Methods
Identiﬁ cation of studies and collection of data
Since 1998, epidemiological studies, published and 
unpublished, have been sought regularly by computer-
aided literature searches, manual searches of review 
articles, written communications, and discussions at 
scientiﬁ c meetings (see appendix p 5 for search strategy). 
Eligible studies are those with information on hormone 
therapy use, parity, oophorectomy and hysterectomy, 
and, if completed after 2006, at least 200 cases of ovarian 
cancer. By January, 2013, 58 such studies were identiﬁ ed 
and principal investigators from each eligible study had 
been invited to collaborate. Datasets from 52 studies are 
included in these analyses and publications from 
three others are reviewed (appendix pp 5–10). 
Cases are postmenopausal women with malignant, or 
borderline-malignant, epithelial or non-epithelial ovarian 
cancer; controls are postmenopausal women without 
ovarian cancer or previous oophorectomy. 
In prospective studies, up to four randomly selected 
matched controls per case were selected. Individual data 
from 51 of the 52 studies were analysed centrally as 
case-control comparisons; because of data protection 
laws, individual data from the Danish Sex Hormone 
Register Study8 could not be exported, so its investigators 
provided detailed tabular results to combine with those 
of other studies (appendix p 6). 
Information was sought for each woman on socio-
demographic, reproductive, and other factors, including 
hormone therapy use before cancer diagnosis for cases 
and to an equivalent time for controls. Postmenopausal 
was deﬁ ned as having reached natural menopause or 
age 55 years (because >90% of women have a natural 
menopause before that age9). Hysterectomy can mask 
natural menopause, so women younger than 55 years 
with a hysterectomy were excluded. Information sought 
about hormone therapy included ever-use, current use, 
age at ﬁ rst and last use, total duration of use, and 
constituents of each preparation. The hormone therapy 
preparation last used was classiﬁ ed as oestrogen-only or 
oestrogen-progestagen (or other/unknown formulation; 
appendix p 6).
Tumour histology was classiﬁ ed as fully malignant or 
borderline-malignant, and as epithelial or not. Epithelial 
tumours were further subdivided into the four most 
common types: serous, endometrioid, mucinous, or 
clear-cell (or mixed/other; appendix p 6). When 
appropriate, the International Classiﬁ cation of Diseases 
for Oncology10 was used.
Full details about information sources, search 
strategy, data collection, and deﬁ nitions are provided in 
the appendix.
Statistical analyses and presentation of results
A protocol was circulated to collaborators and preliminary 
results were discussed at a meeting of investigators in 
July, 2011. Poisson logistic regression comparing particular 
groups of hormone therapy users with never-users yielded 
odds ratios, described here as relative risks (RRs). 
When more than two groups were compared (eg, current-
or-recent users, long-term ex-users, and never-users), the 
variance of the log risk was estimated for each group 
(appendix p 6).11 These group-speciﬁ c variances were 
used to calculate group-speciﬁ c CIs, facilitating valid 
comparisons between any two or more groups, whether or 
not one of them was designated as the baseline group.
The principal analyses include the prospective studies 
only, to avoid any possible biases associated with 
Figure 1: Trends in hormone therapy use in the USA and the UK since 1970
For source of data, see appendix p 4.
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diﬀ erential participation or recall in retrospective studies, 
but throughout the main report sensitivity analyses are 
given that include both the prospective and the 
retrospective studies. Results for the retrospective studies 
only are given in the appendix (pp 17, 19, 20), and 
heterogeneity tests were done to compare results from 
prospective and retrospective studies.
Because women can change their use of hormone 
therapy over time, follow-up in prospective studies was 
censored 4 years after hormone therapy use was last 
recorded (sensitivity analyses explored other cutoﬀ s); 
duration and recency of use were estimated as if the 
last recorded use had continued (ie, duration of use in 
those who were current users when last asked increased 
by 1 year for each year of follow-up, as did time since 
last use of hormone therapy in ex-users). Hence, if in 
a prospective study of hormone therapy use the 
information last recorded before diagnosis is correct, 
then in analyses that combine current users with recent 
ex-users (ie, women who stopped <5 years before 
diagnosis), the current-or-recent users would include 
no misclassiﬁ ed women. Likewise, the never-users are 
contaminated with few hormone therapy users: only 
those who started in the interval of less than 4 years 
before diagnosis, which would be so uncommon 
(appendix p 6) as to dilute only slightly any real eﬀ ects 
of hormone therapy use on risk.
To ensure that women in one study were compared 
directly only with similar women in that same study, all 
analyses were stratiﬁ ed by study, centre within study, age 
(5-year age groups up to 85–89 years), and body-mass 
index (<25, 25–29, or ≥30 kg/m²), and were adjusted for 
parity (0, 1–2, or ≥3), past use of oral contraceptives (never, 
<5 years of use, or ≥5 years of use), and age at menopause 
(natural menopause before age 50 years, natural 
menopause after age 50 years, or previous hysterectomy). 
Unknowns for each variable were assigned to separate 
strata. Sensitivity analyses investigated additional 
adjustment for eight other potential confounding factors. 
Standard χ² tests for heterogeneity were used.
Results were weighted by the amount of statistical 
information in each stratum (inverse of the variance of 
log RR) and are presented as squares and lines, 
representing RRs and CIs (or, where appropriate, 
group-speciﬁ c CIs). Study-speciﬁ c results give 99% CIs 
(to allow for multiple testing), but most other results in 
the ﬁ gures and all results in the text have 95% CIs. To 
illustrate the correspondence between relative and 
absolute risks in hormone therapy users, absolute risks 
were estimated from ovarian cancer incidence rates in 
England (appendix p 11).12 Analyses were done with 
STATA 13.
Role of the funding sources
The study funders had no role in study design, data 
collection, analysis or interpretation, report preparation, 
or the decision to publish. The analysis and writing 
committee had full access to all the data and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Overall information was provided for 21 488 post-
menopausal women with ovarian cancer (cases) from 
52 studies (17 prospective and 35 retrospective; 
appendix pp 7–10). The prospective studies contributed 
more than half of the cases (12 110), with mean 
diagnosis year 2001 (SD 6), 55% (6601) of whom had 
used hormone therapy, with median duration 6 years 
Figure 2: Relative risk of ovarian cancer by duration of use in current and past users of hormone therapy
*Risk relative to never-users of hormone therapy, stratiﬁ ed by age at diagnosis, study, and body-mass index, and adjusted for age at menopause, hysterectomy, oral 
contraceptive use, and parity. p values are two-sided and include the eﬀ ects of the group-speciﬁ c variance in never-users.
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(IQR 2–10). By contrast, in the retrospective studies 
only 29% (2702) of the women had used hormone 
therapy, with median duration 4 years (IQR 1–10), and 
the mean diagnosis year was 1992 (SD 8), well before 
peak hormone therapy use (ﬁ gure 1).
Ovarian cancer risk was signiﬁ cantly greater in 
ever-users than in never-users of hormone therapy 
(RR 1·20, 95% CI 1·15–1·26, p<0·0001 for prospective 
studies; 1·14, 1·10–1·19, p<0·0001 for all studies 
combined; every study-speciﬁ c result is provided in 
Study (country)
Prospective studies
Europe
EPIC (eight European countries)                       
DaHoRS (Denmark)                                  
Million Women Study (UK)                          
Other (Netherlands, Norway, Sweden)               
All Europe
North America
BCDDP (USA)                                       
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All North America
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Figure 3: Study-speciﬁ c results for the relative risk of ovarian cancer for current-or-recent users versus never-users of hormone therapy
For study-speciﬁ c details and references, see appendix pp 7–10. Dotted lines represent totals for all prospective studies and, separately, for all retrospective studies. 
Study-speciﬁ c results are arranged by study design and region; results are given for individual studies with the most statistical information (ie, with variance of 
log relative risk <0·03). Results for the remaining studies are grouped together here (and given separately for every study in appendix p 14). In comparisons of relative 
risks in prospective versus retrospective studies, overall heterogeneity p<0·0001; for European studies, heterogeneity p=0·4; and for North American studies, 
heterogeneity p=0·002. In a comparison of relative risks in prospective studies, Europe versus North American heterogeneity p=0·9; for retrospective studies, Europe 
versus North American heterogeneity p=0·04. References provided in the appendix. *Risk relative to never-users of hormone therapy, stratiﬁ ed by age at diagnosis, 
study, and body-mass index, and adjusted for age at menopause, hysterectomy, oral contraceptive use, and parity.
Articles
www.thelancet.com   Vol 385   May 9, 2015 1839
appendix p 12). Subsequent analyses were restricted to 
women with information both on duration of use and 
on time since last use of hormone therapy; this 
exclusion of studies without information on duration of 
use or time since last use slightly increased these RRs 
(appendix p 13).
Risk was strongly related to recency of use (ﬁ gure 2). 
In prospective studies, risk was greatest in women who 
when last asked had been current users (RR 1·41, 
95% CI 1·32–1·50; p<0·0001). Among them, risk was 
substantial even in those who, at diagnosis, had less 
than 5 years (median duration 3 years) of hormone 
therapy use (RR 1·43, 95% CI 1·31–1·56; p<0·0001).
Risk was, however, also signiﬁ cantly increased in 
women who had been recent ex-users and would at the 
time of diagnosis have still have been within 5 years of 
last use (RR 1·23, 95% CI 1·09–1·37; p=0·0006 in 
prospective studies). Risk decreased the longer ago 
hormone therapy had last been used, although women 
who had used hormone therapy for at least 5 years 
(median duration 9 years) and then stopped were still at 
signiﬁ cantly increased risk more than 5 years 
(median time since last use 10 years) later (RR 1·10, 
95% CI 1·01–1·20; p=0·02). For prospective and 
retrospective studies combined, the risks were similar to 
those in prospective studies alone, except that the risks in 
current users seemed to be somewhat smaller (ﬁ gure 2, 
appendix p 17).
In prospective studies the risk for current-or-recent 
hormone therapy use (ie, use within the past 5 years) 
was 1·37 (95% CI 1·27–1·48; ﬁ gure 3). This RR did 
not diﬀ er signiﬁ cantly between European and North 
American studies (1·37 vs 1·35; heterogeneity p=0·9).
However, the RR for current-or-recent hormone 
therapy use did diﬀ er signiﬁ cantly between prospective 
and retrospective studies (1·37 vs 1·04; heterogeneity 
p<0·0001; ﬁ gure 3, appendix p 14). This diﬀ erence was 
due to the lack of apparent eﬀ ect in the aggregated 
North American retrospective studies (ﬁ gure 1, appendix 
pp 12–14). In these retrospective studies, however, the 
design might have made unbiased recruitment of 
controls diﬃ  cult, and the average year of diagnosis for 
the cases was 1990, well before hormone therapy use 
had become common (ﬁ gure 1).
Sensitivity analyses left the main ﬁ ndings in prospective 
studies largely unchanged (appendix p 18). For example, 
adjustment for eight additional factors (year of birth, 
ethnic origin, education, age at menarche, height, alcohol 
consumption, smoking, and family history of ovarian or 
breast cancer) altered the RRs in current-or-recent users 
by 0·02 or less (the main ﬁ ndings had already been 
stratiﬁ ed by study, age, and body-mass index, and 
Relative risk for current-or-
recent users vs never-users 
of hormone therapy (95% CI)*
Relative risk for current-or-
recent users vs never-users 
of hormone therapy (95% CI)*
Prospective studies All studiesCases 
(prospective/
all studies)
Serous tumours
All types of hormone therapy                         1286/2208 1·53 (1·40–1·66)
Oestrogen-only hormone therapy                       487/914 1·58 (1·39–1·80)
Oestrogen-progestagen hormone therapy                543/838 1·55 (1·38–1·74)
Endometrioid tumours
All types of hormone therapy                            298/508 1·42 (1·20–1·67)
Oestrogen-only hormone therapy                       114/222 1·34 (1·05–1·72)
Oestrogen-progestagen hormone therapy                127/192 1·58 (1·26–1·98)
Mucinous tumours
All types of hormone therapy                          203/303 0·93 (0·77–1·12)
Oestrogen-only hormone therapy                       79/122 1·00 (0·75–1·33)
Oestrogen-progestagen hormone therapy                88/122 0·95 (0·73–1·24)
Clear-cell tumours
All types of hormone therapy                            92/172 0·75 (0·57–0·98)
Oestrogen-only hormone therapy                       28/57 0·81 (0·53–1·25)
Oestrogen-progestagen hormone therapy                43/75 0·70 (0·47–1·04)
0·5 1·0 1·5 2·0
1·40 (1·31–1·49)
1·59 (1·45–1·75)
1·39 (1·26–1·53)
1·28 (1·13–1·45)
1·42 (1·19–1·69)
1·29 (1·08–1·55)
0·80 (0·69–0·93)
0·88 (0·71–1·10)
0·83 (0·67–1·03)
0·80 (0·65–0·98)
0·91 (0·66–1·24)
0·76 (0·57–1·02)
0·5 1·0 1·5 2·0
Figure 4: Relative risk of the four most common subtypes of ovarian cancer in current-or-recent users versus never-users of hormone therapy
Numbers do not add to totals, because some hormone therapy users were classiﬁ ed as using other or unknown types of hormone therapy and some epithelial 
tumours are classiﬁ ed as mixed types, other type, or type not speciﬁ ed. *Risks relative to never-users of hormone therapy, stratiﬁ ed by age at diagnosis, study, and 
body-mass index, and adjusted for age at menopause, hysterectomy, oral contraceptive use, and parity.
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adjusted for parity, use of hormonal contraceptives, age 
at menopause, and hysterectomy).
Furthermore, the main ﬁ ndings were robust against 
variation in follow-up duration. Censoring either earlier 
or later than year 4 (appendix p 18) made little diﬀ erence 
to the results. Two prospective studies (in the UK5 and 
Denmark8) contributed the most statistical information, 
but the RR in all other prospective studies was much the 
same when these two were excluded. One prospective 
study13 used fatal ovarian cancer as the outcome, but 
again its ﬁ ndings were typical.
In current-or-recent users, ovarian cancer risk was 
signiﬁ cantly increased with use of both oestrogen-only 
and oestrogen-progestagen preparations, with little 
heterogeneity between the risks: RR 1·37 (95% CI 
1·26–1·50) and 1·37 (1·26–1·48), respectively, in the 
prospective studies (heterogeneity p=0·9); and 
1·32 (1·23–1·41) and 1·25 (1·16–1·34) in all studies 
(heterogeneity p=0·3; appendix p 17). Few women had 
used both these classes of hormone therapy, and within 
the two classes there was insuﬃ  cient information to 
assess whether risk varied by hormone therapy 
formulation or mode of delivery (appendix p 6).
All but three studies provided tumour histology 
(appendix p 6). Of tumours with known histology, 
98% (14 862 of 15 090) were epithelial. The RR in 
current-or-recent users versus never-users did not seem 
to diﬀ er between epithelial (RR 1·28, 95% CI 1·22–1·34) 
and non-epithelial (1·35, 0·90–2·02) tumours, although 
the conﬁ dence interval for non-epithelial tumours was 
wide. There were only 228 non-epithelial tumours, too 
few for further analysis.
Almost all epithelial tumours of known, unmixed 
histology were adenocarcinomas of four main tumour 
types which were, in decreasing order of frequency, 
serous (7406 cases), endometrioid (1749), mucinous 
(1434), and clear cell (766). These four epithelial tumour 
types had qualitatively diﬀ erent relationships with 
hormone therapy use, both in prospective studies alone 
and in all studies combined (ﬁ gure 4; heterogeneity 
p<0·0001).
In prospective studies, risks in current-or-recent users 
were deﬁ nitely increased only for the two most common 
tumour types, serous (RR 1·53, 95% CI 1·40–1·66, 
p<0·0001) and endometrioid (1·42, 1·20–1·67; p<0·0001). 
In the aggregate of these two types, the risk more than 
5 years since last use for past users who had used 
hormone therapy for more than 5 years (RR 1·25, 
95% CI 1·07–1·46; p=0·005) was more deﬁ nite than in 
the aggregate of all types (1·10, 1·01–1·20, p=0·02). Risk 
might have been somewhat decreased for the least 
common type, clear-cell tumours (RR 0·75, 95% CI 
0·57–0·98; p=0·04 before any allowance for multiple 
hypothesis testing), but this protective eﬀ ect is not 
statistically deﬁ nite, and in the aggregate of both of the 
less common types the risk reduction was not signiﬁ cant 
(RR 0·86, 0·74–1·01; p=0·07). Within each tumour type 
there was little diﬀ erence between the RRs for oestrogen-
only and oestrogen-progestagen prepara tions (ﬁ gure 4), 
or for borderline and fully malignant tumours (appendix 
p 19).
Age at initiation of hormone therapy had little eﬀ ect; the 
RRs in current-or-recent users were similarly elevated with 
hormone therapy use beginning before age 50 years 
(RR 1·35, 95% CI 1·24–1·47) and at age 50–59 years 
(1·31, 1·22–1·40), with little information about older ages 
(1·15, 0·93–1·43; appendix p 20). Likewise, the available 
evidence suggested no major heterogeneity across 
subgroups deﬁ ned by smoking, body size, parity, past use 
of oral contraceptives, hysterectomy, or other characteristics 
(appendix pp 15–16).
Application of the RRs in the prospective studies to age-
speciﬁ c ovarian cancer incidence and death rates in 
England suggested that 5 years of hormone therapy use, 
starting at around 50 years of age, would result in 
about one additional ovarian cancer per 1000 users and 
one additional ovarian cancer death per 1700 users 
(appendix p 11); 10 years of hormone therapy use from 
around 50 years of age would result in about one additional 
ovarian cancer per 600 users and one additional ovarian 
cancer death per 800 users (table).
Discussion
This collaboration brought together and analysed 
centrally individual data from 52 epidemiological studies, 
in which about half the postmenopausal women with 
ovarian cancer had used hormone therapy. Ovarian 
cancer risk was signiﬁ cantly increased in current users, 
even in those with less than 5 years hormone therapy 
use. In ex-users, risks decreased the longer ago hormone 
therapy use had ceased, but risks during the ﬁ rst few 
years after stopping remained appreciable. Furthermore, 
about a decade after ceasing long-duration hormone 
therapy use, there still seemed to be a small excess risk.
In current-or-recent users (all of whom had used 
hormone therapy within the past 5 years), the RRs did 
not diﬀ er signiﬁ cantly between users of oestrogen-only 
and of oestrogen-progestagen preparations, or between 
5 year incidence of 
ovarian cancer per 
1000 never-users of 
hormone therapy
Absolute 5 year excess 
incidence per 1000 users 
with 5 years of hormone 
therapy use
Absolute 5 year excess 
incidence per 1000 users 
with 10 years of hormone 
therapy use
Age 50–54 years 1·2 0·52 0·52
Age 55–59 years 1·6 0·37 0·67
Age 60–64 years 2·1 0·10 0·61
Excess incidence ·· 0·99 per 1000; 
1 in 1000 users
1·80 per 1000; 
1 in 600 users
Excess deaths ·· 0·6 per 1000; 
1 in 1700 users
1·2 per 1000; 
1 in 800 users
Methods and sources of data are provided in appendix p 11. 
Table: Estimated excess incidence of ovarian cancer in England associated with 5 years and with 10 years 
of hormone therapy use, starting at age 50 years
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women who had started hormone therapy before the 
age of 50 years or during their 50s. The RR did, 
however, vary substantially by tumour type, being 
increased only for the two most common histological 
types, serous and endometrioid tumours. In analyses 
restricted to these two types, the excess risk about a 
decade after ceasing long duration hormone therapy 
use became more deﬁ nite.
An important strength of prospective studies is that 
recruitment takes place and information about hormone 
therapy use is recorded before women know whether 
they will develop ovarian cancer. The robustness of 
prospective data is demonstrated by the stability of the 
ﬁ ndings in various sensitivity analyses, and by the 
similarity of the ﬁ ndings in Europe and North America. 
Prospective studies provided more than half the statistical 
information, so results for all studies (prospective and 
retrospective combined) were broadly similar to those for 
the prospective studies alone.
When the retrospective studies were assessed in 
isolation, their aggregate ﬁ ndings diﬀ ered from those of 
the prospective studies, however, perhaps because of 
biases in some retrospective studies. Many retrospective 
study results could have been somewhat biased by 
selective participation of hormone therapy users, and in 
all retrospective studies information about hormone 
therapy use was recorded after cancer diagnosis, so there 
might have been diﬀ erential recall of hormone therapy 
use. Moreover, some retrospective datasets in this 
collaboration have yielded apparently discrepant 
ﬁ ndings on the association of ovarian cancer risk with 
smoking14 and with body-mass index.15
Almost all the worldwide evidence from eligible 
epidemiological studies was included in this 
meta-analysis. The three eligible studies that had 
published results but did not contribute data were all 
retrospective and North American, and had all reported 
increased risks of ovarian cancer associated with some 
aspect of hormone therapy use (appendix p 5). Had 
they been included, the ﬁ ndings in North American 
retrospective studies might not have been as diﬀ erent 
from those in other groups of studies.
As long as current users and recent ex-users are 
combined together as current-or-recent users, there are 
fewer potential sources of bias in prospective than in 
retrospective studies, and there is now for the ﬁ rst time 
suﬃ  cient evidence from prospective studies alone for 
statistically stable meta-analyses. Hence, it is now 
possible to base the main conclusions on prospective 
study results.
The overall relative risk for any type of ovarian cancer 
is the key public health outcome. There are, however, 
four main types of ovarian cancer, and in the prospective 
studies risk was deﬁ nitely increased only for the 
two most common types, serous and endometrioid. 
Risk was possibly, although not deﬁ nitely, decreased for 
the least common type, clear-cell tumours. Although 
tumour histology could have been classiﬁ ed in slightly 
diﬀ erent ways in diﬀ erent studies, any misclassiﬁ cation 
would tend to blur diﬀ erences by tumour type, yet we 
noted distinctly heterogeneous RRs. This heterogeneity 
argues strongly for causality, because it implies that the 
hormone-therapy-associated risks were not due just to 
confounding and that diﬀ erent ovarian cancer types 
have diﬀ ering causes. The reasons for this heterogeneity 
are unclear, partly because the sites of origin of the 
four main tumour types are uncertain.16 The dependence 
of risk on ovarian tumour type is quite diﬀ erent for 
other exposures; oral contraceptives decrease serous, 
endometrioid, and clear-cell but not mucinous 
tumours,17 whereas smoking decreases endometrioid 
and clear-cell but increases mucinous tumours.14
The ﬁ ndings that ovarian cancer risk is greatest in 
current users of hormone therapy, falls after use ceases, 
and varies by tumour type, strongly suggest a causal 
relationship—ie, that among otherwise similar women, 
use of hormone therapy increases the probability of 
developing the two most common types of ovarian 
cancer, and hence ovarian cancer as a whole. There are 
still some 6 million users of hormone therapy in the 
USA and the UK, in addition to a comparable number in 
other high-income countries (ﬁ gure 1, appendix p 4). At 
present, the WHO, European, and US guidelines about 
hormone therapy do not mention ovarian cancer, and the 
UK guidelines (which are due to be revised) state only 
that risk may be increased with long-term use. The 
deﬁ nite risk of ovarian cancer that is observed even with 
less than 5 years of use starting at around age 50 years is 
directly relevant to current patterns of hormone therapy 
use, and hence directly relevant to medical advice, 
personal choices, and the current eﬀ orts to revise UK 
and worldwide guidelines.
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